Stephan Joseph Dorkhom DO

Hematology/Medical Oncology

Summary

Dr. Stephan Dorkhom is The Chairman of Medicine at St. Joseph's-Wayne Hospital and a Triple Board Certified Hematologist/Oncologist in Wayne, NJ affiliated with multiple hospitals in the area, including St Joseph's Wayne Hospital and St. Joseph's University Medical Center. He received his medical degree from New York College of Osteopathic Medicine at the top of his class and has been in practice 10 years. He also speaks multiple languages, including Arabic and Spanish. He specializes and is board certified in both hematology and oncology and is experienced in all solid cancers (breast, colon, lung, pancreas, stomach, liver, prostate, ovarian/endometrial, testicular, melanoma/skin, brain), amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2007 - 2010
NYIT College Of Osteopathic MedicineClass of 2007
Colgate UniversityBA, Molecular Biology, Honors Molecular Biology/Cum Laude, 1998 - 2002

Chairman of Medicine St. Joseph's-Wayne Hospital
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2014, 2016-2017

PubMed

60 citations
Hepatocellular carcinoma in two patients with cardiac cirrhosis.
Teddy Saliba, Stephan Dorkhom, Eileen M. O'Reilly, Emmy Ludwig, Bolorsukh Gansukh
European Journal of Gastroenterology & Hepatology. 2010-07-01
31 citations
Novel Kelch-like Protein, KLEIP, Is Involved in Actin Assembly at Cell-Cell Contact Sites of Madin-Darby Canine Kidney Cells
Takahiko Hara, Hiroshi Ishida, Razi Raziuddin, Stephan Dorkhom, Keiju Kamijo
Molecular Biology of the Cell. 2003-12-10

Books/Book Chapters

Advances in the Treatment of Chronic Myeloid Leukemia
Chapter: Treatment options for tyrosine kinase inhibitor-resistant chronic myeloid leukemia
Page 78 - 96Stephan Joseph Dorkhom, Hady Ghanem, and Elias JabbourUnitec House (Future Medicine Ltd), London N3 1QB, United Kingdom2013

Abstracts/Posters

Interim Analysis of a Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.
Dorkhom, SJ, Thomas SK, Alexanian R, Shah J, Webber DM, Wang M, Anderson ML, Morales de Partovie C, Ghandi VV, Orlowski RZ, American Society of Hematology National Meeting, The University of Texas MD Anderson Cancer Center, 12/2012
Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagno...
Mathisen M, Kantarjian H, Faderl S, Garcia-Manero G, Ravandi F, Kadia TM, Daver NG, O'Brien SM, Dorkhom SJ, Pierce S, Lira C, Cortes JE, Jabbour E, American Society of Clinical Oncology National Meeting, The University of Texas MD Anderson Cancer Center, 6/2012
Allogenic stem cell transplant (ASCT) as initial salvage for patients with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy
Daver NG, De Lima M JG, Kantarjian H, Ravandi F, Asim Bilen M, Pierce S, Khouri IF, Dorkhom SJ, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE,..., American Society of Clinical Oncology National Meeting, The University of Texas MD Anderson Cancer Center, 6/2012

TV Special ABChttp://www.everythinglubbock.com/story/d/story/heartbeat-7-20-14-radio-host-diagnosed-with-cancer/40185/3G8BaYeqV0ySciwpAQ9M6Q
TV Special ABChttp://www.everythinglubbock.com/story/d/story/prostate-cancer-importance-of-getting-screened/38943/wSfCf9wXfUKlV4APeiDwQQ
TV Special NBChttp://m.kcbd.com/kcbd/db_/contentdetail.htm?full=true&contentguid=od%3a0IRTOpCQ&pn=&ps=#display